• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Inozyme Pharma, Inc. - Common Stock (NQ:INZY)

4.000 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.000
Bid (Size) 3.990 (689)
Ask (Size) 4.010 (44)
Prev. Close 4.000
Today's Range 4.000 - 4.000
52wk Range 0.7210 - 6.240
Shares Outstanding 61,729,666
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
June 20, 2025
From Inozyme Pharma Inc.
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates INZY, TXNM, SVT, PTIX on Behalf of Shareholders
May 27, 2025
From Halper Sadeh LLC
Via GlobeNewswire

Performance

YTD
+40.4%
+40.4%
1 Month
N/A
N/A
3 Month
+230.6%
+230.6%
6 Month
+174.0%
+174.0%
1 Year
-31.0%
-31.0%

More News

Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
May 27, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
INOZYME PHARMA INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inozyme Pharma, Inc. - INZY
May 21, 2025
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Inozyme Pharma, Inc. (Nasdaq – INZY), TXNM Energy, Inc. (NYSE - TXNM), Servotronics, Inc. (NYSE American - SVT), Protagenic Therapeutics, Inc. (Nasdaq – PTIX)
May 19, 2025
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SWTX, NVEE, CHTR, INZY on Behalf of Shareholders
May 18, 2025
From Halper Sadeh LLC
Via GlobeNewswire
Gold Down Over 1%; Flowers Foods Posts Weak Earnings
May 16, 2025
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
May 16, 2025
Via Benzinga
Inozyme Stock Rockets 179% After BioMarin Agrees To Acquire The Company For $270M: Retail Sentiment Brightens
May 16, 2025
Via Stocktwits
Synergy CHC Corp. (NASDAQ: SNYR) Reports Strong Q1, Signals 2025 Expansion in GLP-1 and Global Markets – More Stocks Inside
May 16, 2025
Via AB Newswire
US Stocks Edge Higher; Consumer Sentiment Falls In May
May 16, 2025
Via Benzinga
INZY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inozyme Pharma, Inc. Is Fair to Shareholders
May 16, 2025
From Halper Sadeh LLC
Via Business Wire
BioMarin Bolsters Pipeline With $270 Million Inozyme Pharma Takeover
May 16, 2025
Via Investor's Business Daily
Shareholder Alert: The Ademi Firm investigates whether Inozyme Pharma, Inc. is obtaining a Fair Price for its Public Shareholders
May 16, 2025
From Ademi & Fruchter LLP
Via Business Wire
12 Health Care Stocks Moving In Friday's Pre-Market Session
May 16, 2025
Via Benzinga
Inozyme Pharma Reports First Quarter 2025 Financial Results and Provides Business Highlights
May 14, 2025
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces JBMR Plus Publication Demonstrating Real-World Impact of ENPP1 Deficiency
April 10, 2025
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference
March 31, 2025
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights
March 10, 2025
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference
February 24, 2025
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025
February 21, 2025
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates
January 10, 2025
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
November 27, 2024
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma to Present at Upcoming Investor Conferences
November 11, 2024
From Inozyme Pharma Inc.
Via GlobeNewswire
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
November 05, 2024
From Inozyme Pharma Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Inozyme Pharma, Inc. - Common Stock publicly traded?
Yes, Inozyme Pharma, Inc. - Common Stock is publicly traded.
What exchange does Inozyme Pharma, Inc. - Common Stock trade on?
Inozyme Pharma, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Inozyme Pharma, Inc. - Common Stock?
The ticker symbol for Inozyme Pharma, Inc. - Common Stock is INZY on the Nasdaq Stock Market
What is the current price of Inozyme Pharma, Inc. - Common Stock?
The current price of Inozyme Pharma, Inc. - Common Stock is 4.000
When was Inozyme Pharma, Inc. - Common Stock last traded?
The last trade of Inozyme Pharma, Inc. - Common Stock was at 06/30/25 04:00 PM ET
What is the market capitalization of Inozyme Pharma, Inc. - Common Stock?
The market capitalization of Inozyme Pharma, Inc. - Common Stock is 246.92M
How many shares of Inozyme Pharma, Inc. - Common Stock are outstanding?
Inozyme Pharma, Inc. - Common Stock has 247M shares outstanding.
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap